Six Cases of Esophagogastric Junctional Cancer Successfully Treated with Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy(NAC)is prescribed for resectable esophagogastric junctional cancer on the basis of esophageal invasion length, lymph node metastasis, and pathological diagnosis. Due to a lack of consensus in Japan, however, discussion regarding its use is necessary. This study comprised 6 p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gan to kagaku ryoho Ročník 50; číslo 13; s. 1685
Hlavní autoři: Hiroi, So, Fukuda, Shintaro, Yamahata, Yuto, Otani, Takahiro, Tada, Tetsuya, Hirukawa, Hiroshi
Médium: Journal Article
Jazyk:japonština
Vydáno: Japan 01.12.2023
Témata:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - pathology
Esophageal Neoplasms - surgery
Esophagogastric Junction - pathology
Esophagogastric Junction - surgery
Female
Gastrectomy
Humans
Male
Neoadjuvant Therapy
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
ISSN:0385-0684
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Neoadjuvant chemotherapy(NAC)is prescribed for resectable esophagogastric junctional cancer on the basis of esophageal invasion length, lymph node metastasis, and pathological diagnosis. Due to a lack of consensus in Japan, however, discussion regarding its use is necessary. This study comprised 6 patients who underwent surgical resection after receiving NAC in our department from 2018 to 2022. All the patients were male, with a median age of 67 years. Three patients underwent SP therapy, 2 received SOX therapy, and 1 received both SOX and HER therapy. A total gastrectomy was performed in 3 cases, a fundectomy in 1 case, and a subtotal esophagectomy with gastric tube reconstruction in 2 cases. The histological types were tub2 in 3 cases; and tub1 plus pap, por1 plus pap, and NEC in 1 case each, respectively. One case was ypStage ⅠA, 2 cases were ⅠB, 1 was ⅡA, 1 was ⅡB and 1 was pCR. Currently, all the patients remain alive and without recurrence. NAC has, therefore, been demonstrated to be an effective therapeutic strategy for esophagogastric junctional cancer in this study. However, further research with a larger sample size is required.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0385-0684